Diagnosis and treatment of endocrinological complications of immunotherapy of oncological diseases

Ekaterina A. Pigarova; Larisa K. Dzeranova; Nurana F. Nuralieva; Galina A. Mel`nichenko

doi:10.14341/omet9834

Diagnosis and treatment of endocrinological complications of immunotherapy of oncological diseases

Ekaterina A. Pigarova, Larisa K. Dzeranova, Nurana F. Nuralieva, Galina A. Mel`nichenko

https://doi.org/10.14341/omet9834

Full Text:

PDF (Rus) HTML (Rus) XML (Rus)

Generate QR code

Abstract

In this lecture, we discuss in detail the endocrinopathies associated with the use of immune-checkpoint inhibitors in oncology. The cases, terms and features of clinical manifestations of endocrine-related immune reactions are discussed, and practical recommendations for the treatment of patients are proposed.

Keywords

immune-checkpoint inhibitors, ipilimumab, nivolumab, endocrinopathies, autoimmune diseases, adverse effects, thyroiditis, pituitary, adrenal insufficiency, adrenalitis, hypothyroidism, melanoma, lung cancer, CTLA-4, PD-1

About the Authors

Ekaterina A. Pigarova

Endocrinology Research Centre

Russian Federation

MD, PhD

Larisa K. Dzeranova

Endocrinology Research Centre

Russian Federation

MD, PhD

Nurana F. Nuralieva

Endocrinology Research Centre

Russian Federation

Galina A. Mel`nichenko

Endocrinology Research Centre

Russian Federation

MD, PhD, Professor

References

1. Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat. Rev. 2016;44:51-60. doi: 10.1016/j.ctrv.2016.02.001.

2. Byun DJ, Wolchok JD, Rosenberg LM, Girotra M. Cancer immunotherapy – immune checkpoint blockade and associated endocrinopathies. Nature Reviews Endocrinology. 2017;13(4):195-207. doi: 10.1038/nrendo.2016.205.

3. Zhao C, Tella SH, Del Rivero J, et al. Anti–PD-L1 Treatment Induced Central Diabetes Insipidus. J. Clin. Endocr. Metab. 2018;103(2):365-369. doi: 10.1210/jc.2017-01905.

4. Min L. Immune-related endocrine disorders in novel immune checkpoint inhibition therapy. Genes & Diseases. 2016;3(4):252-256. doi: 10.1016/j.gendis.2016.10.002.

5. Hofmann L, Forschner A, Loquai C, et al. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur. J. Cancer. 2016;60:190-209. doi: 10.1016/j.ejca.2016.02.025.

6. Weber JS, Kähler KC, Hauschild A. Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab. J. Clin. Oncol. 2012;30(21):2691-2697. doi: 10.1200/jco.2012.41.6750.

7. Iwama S, De Remigis A, Callahan MK, et al. Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody. Sci. Transl. Med. 2014;6(230):230ra245-230ra245. doi: 10.1126/scitranslmed.3008002.

8. Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline. J. Clin. Endocr. Metab. 2016;101(2):364-389. doi: 10.1210/jc.2015-1710.

9. Tsiogka A, Jansky GL, Bauer JW, Koelblinger P. Fulminant type 1 diabetes after adjuvant ipilimumab therapy in cutaneous melanoma. Melanoma Res. 2017;27(5):524-525. doi: 10.1097/cmr.0000000000000384.

10. Wang Z, Zheng Y, Tu Y, et al. Immunological Aspects of Fulminant Type 1 Diabetes in Chinese. Journal of Immunology Research. 2016;2016:1-6. doi: 10.1155/2016/1858202.

11. Hughes J, Vudattu N, Sznol M, et al. Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy. Diabetes Care. 2015;38(4):e55-7. doi: 10.2337/dc14-2349.

12. Win MA, Thein KZ, Qdaisat A, Yeung S-CJ. Acute symptomatic hypocalcemia from immune checkpoint therapy-induced hypoparathyroidism. The American Journal of Emergency Medicine. 2017;35(7):1039.e1035-1039.e1037. doi: 10.1016/j.ajem.2017.02.048.

13. Zhao C, Tella SH, Del Rivero J, et al. Anti–PD-L1 Treatment Induced Central Diabetes Insipidus. J. Clin. Endocr. Metab. 2018;103(2):365-369. doi: 10.1210/jc.2017-01905.

14. Дедов И.И., Мельниченко Г.А., Пигарова Е.А., и др. Федеральные клинические рекомендации по диагностике и лечению несахарного диабета у взрослых. // Ожирение и метаболизм. – 2018. – Т.15. – No. 2 – С. 56-71. [Dedov II, Mel'nichenko GA, Pigarova EA, et al. Federal clinical guidelines on diagnosis and treatment of diabetes insipidus in adults. Obesity and metabolism. 2018;15(2):56-71. (in Russ.)] doi: 10.14341/omet9670.

Supplementary files

	1. Fig. 1. The frequency of autoimmune-mediated adverse events in the use of immune endpoint inhibitors [1–5].
	Subject
	Type	Исследовательские инструменты
	View (64KB)	Indexing metadata ▾

	2. Fig. 2. Schematic representation of the phase flow of thyroiditis.
	Subject
	Type	Исследовательские инструменты
	View (109KB)	Indexing metadata ▾

	3. Fig. 3. Algorithm for the differential diagnosis of diabetes insipidus [14].
	Subject
	Type	Исследовательские инструменты
	View (124KB)	Indexing metadata ▾

Review

For citations:

Pigarova E.A., Dzeranova L.K., Nuralieva N.F., Mel`nichenko G.A. Diagnosis and treatment of endocrinological complications of immunotherapy of oncological diseases. Obesity and metabolism. 2018;15(3):49-58. (In Russ.) https://doi.org/10.14341/omet9834

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).

ISSN 2071-8713 (Print)
ISSN 2306-5524 (Online)

Username
Password
	Remember me
Not a user? Register with this site Forgot your password?

	Title	Fig. 1. The frequency of autoimmune-mediated adverse events in the use of immune endpoint inhibitors [1–5].
	Type	Исследовательские инструменты
	Date	2018-11-23
Digital Object Identifier	https://doi.org/10.14341/omet9834-3364

	Title	Fig. 2. Schematic representation of the phase flow of thyroiditis.
	Type	Исследовательские инструменты
	Date	2018-11-23
Digital Object Identifier	https://doi.org/10.14341/omet9834-3365

	Title	Fig. 3. Algorithm for the differential diagnosis of diabetes insipidus [14].
	Type	Исследовательские инструменты
	Date	2018-11-23
Digital Object Identifier	https://doi.org/10.14341/omet9834-3366

User

Obesity and metabolism

Diagnosis and treatment of endocrinological complications of immunotherapy of oncological diseases

Full Text:

Abstract

Keywords

About the Authors

References

Supplementary files

Review

For citations:

Cookies policy